BillionToOne Inc. Class A Common Stock (BLLN)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials
BillionToOne a molecular diagnostic company from California, has experienced quite a topsy-turvey journey since its debut in November last year. BLLN is set to hold on to a consistently high GMS of 70%, which reflects the capabilities of its unique QCT technology that underpins its oncology and prenatal diagnostics product suite. BLLN trades at a slight EV/sales discount to peers but offers best-in-class forward topline growth of 38% p.a., far outpacing the industry average of 22%.
BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Billiontoone Q2 Earnings Call Highlights
Billiontoone NASDAQ: BLLN reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular diagnostics company also posted positive operating income and free cash flow while reiterating its full-year revenue outlook.
BillionToOne Inc. Class A Common Stock Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 186 | $14,832.9 | $20,515.73 | $5,682.83 | 38.31% |
| GN Gina Nelson Next Century Growth Investors LLC | 364,467 | $35.73M | $40.42M | $4.69M | 13.12% |
| SRD Sara R. Dasse Adams Street Partners LLC | 1.71M | $140.06M | $184.95M | $44.89M | 32.05% |
| DRO Donal Reamonn O'Sullivan Brevan Howard Capital Management LP | 7,716 | $622,316.32 | $849,531.6 | $227,215.28 | 36.51% |
| TN Tiffany Ng Renaissance Capital LLC | 7,495 | $756,402.44 | $807,736.15 | $51,333.71 | 6.79% |
BillionToOne Inc. Class A Common Stock Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SN Subbu Nambi Guggenheim | 197.04 | $20,839.24 | $21,866.82 | $1,027.58 | 4.93% |
BillionToOne Inc. Class A Common Stock (BLLN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BillionToOne Inc. Class A Common Stock ever had a stock split?
BillionToOne Inc. Class A Common Stock Profile
| Professional Services Industry | Industrials Sector | Oguzhan Atay CEO | NASDAQ (NGS) Exchange | 090168105 CUSIP |
| US Country | 713 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BillionToOne, Inc. is a precision diagnostics company that specializes in quantifying biological elements to develop advanced molecular diagnostics. By utilizing a molecular counting platform, the company aims to detect and measure DNA molecules at the single-count level, which significantly enhances the ability to detect diseases. Founded in 2016 and headquartered in Menlo Park, California, BillionToOne is engaged in pioneering efforts to improve proactive healthcare solutions through innovative testing methods.
Products and Services
- UNITY Complete: This is a non-invasive prenatal screening test that evaluates the risk of fetal aneuploidies, recessive conditions, and fetal antigens. The test requires only a maternal blood draw for assessment, making it an accessible option for expectant mothers seeking crucial information about their pregnancy.
- Northstar Select: A liquid biopsy test designed specifically for oncology applications. This test identifies mutations present in the tumor by analyzing circulating tumor DNA (ctDNA). It encompasses a variety of mutations, including deletions, insertions, and point mutations, which helps clinicians tailor treatment strategies based on the genetic profile of an individual's tumor.
- Northstar Response: This test provides longitudinal assessment of cancer burden by evaluating methylation patterns in cfDNA (circulating free DNA). By determining changes over time, healthcare providers can monitor the effectiveness of treatments and make informed decisions on patient care.
Contact Information
